A new study indicates that metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), is on track to impact approximately 1.8 billion individuals globally by 2050. The alarming rise is attributed to escalating rates of obesity, high blood sugar levels, and lifestyle changes. Currently, an estimated 1.3 billion people are living with MASLD, a figure that has surged by 143% over the past thirty years.
Rising Prevalence of MASLD
The findings, published in the *Lancet Gastroenterology & Hepatology*, shed light on the rapid escalation of MASLD, now affecting about one in six individuals worldwide, or 16% of the global population. In 1990, the condition was present in approximately 500 million people; by 2023, this number had more than doubled, reaching 1.3 billion. Projections indicate a further increase of 42% by 2050, raising urgent concerns about the public health implications of this trend.
The prevalence rate has surged to 14,429 cases per 100,000 people in 2023, marking a substantial 29% increase since 1990. While men are more likely to be affected than women, the prevalence is particularly pronounced among older adults aged 80 to 84. However, the largest demographic of those affected is younger adults, specifically men aged 35 to 39 and women aged 55 to 59.
Key Drivers of MASLD
The study identifies high blood sugar as the primary contributor to MASLD-related health complications, followed closely by high body mass index (BMI) and smoking. These findings underline the disease’s strong associations with type 2 diabetes and obesity. Certain regions, especially North Africa and the Middle East, exhibit disproportionately higher rates of MASLD compared to others, yet significant increases have been observed in countries worldwide.
In the United Kingdom, for example, the prevalence of MASLD has surged by 33% since 1990, the highest rate of increase in Western Europe. Australia and the United States have also seen notable rises of 30% and 22%, respectively, according to an analysis conducted by the *Guardian*.
Health Impact and Future Risks
Despite the rising number of MASLD cases, the overall health impact, measured in years lost due to illness or premature death, has remained stable. This stability suggests that advancements in treatment and patient care are enabling individuals to live longer, healthier lives, even as more people are diagnosed with the disease. However, the growing prevalence of MASLD raises concerns about the potential for serious complications, such as liver cirrhosis and cancer, in the future.
Often asymptomatic, MASLD may go unnoticed until detected through tests for unrelated conditions. Some individuals may experience fatigue, general malaise, or discomfort in the liver area, typically situated beneath the lower right ribcage. The condition is closely tied to being overweight and can be effectively managed through lifestyle modifications.
A Call to Action
Led by the Institute for Health Metrics and Evaluation at the University of Washington, the research highlights the increasing incidence of MASLD among younger adults, reflecting broader trends in public health and lifestyle choices. The authors advocate for heightened recognition of MASLD as a global health priority, underscoring the need for targeted policies, awareness campaigns, and interventions to address its rising prevalence and mitigate future health complications.
Why it Matters
The projected spike in MASLD cases represents a significant public health challenge that could overwhelm healthcare systems if left unaddressed. As lifestyle-related illnesses continue to proliferate, it is imperative that governments and health organisations prioritise preventive measures and education to combat the underlying risk factors, such as obesity and diabetes. Addressing MASLD not only improves individual health outcomes but also alleviates future burdens on healthcare resources, making it a critical focus for global health initiatives.
